Cerenis Therapeutics Completes Phase I Clinical Trial Of CER-002 For Treatment Of Cardiovascular Disease Cerenis Therapeutics SA (Cerenis), a privately held pharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, announced that it has completed a Phase I clinical trial for CER-002, one of the company's lead product candidates.
Source: www.medicalnewstoday.comLabels: No Prescription, Online Pharmacy
# posted by Network @ 9:00 PM
